Market Cap
$1.7B
XERS
Xeris Biopharma Holdings, Inc.
$9.08 ▼ -1.84%
Prev close $9.25Market cap$1.7B
ConsensusStrong Buy
12-mo target$12.29 (+35.3%)
▲ Bullish
Analyst conviction 9/10
Insider Selling Cluster (3 insiders)High Impact Filing (7/10)30 New Institutional Positions16 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on XERS right now — valuation, ownership and activity at a glance.
Cap Size
Small Cap
Analyst Consensus
Strong Buy (85%)
Inst. Holders
50 funds
Inst. Value
$667.7M
Inst. Activity
30 buys / 16 sells
Insider Activity
$0.00 buy / $3.4M sell
Insider Net $
-$3.4M
SEC Reports
14
Price chart 30d +5.7%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 1, 2026 Insider
McCulloch Kevin sold 15,000 shares
See Remarks @ $9.41 ($141.1K)
Oct 1, 2026 Insider
Hecht Beth sold 16,666 shares
See Remarks @ $9.41 ($156.8K)
Oct 1, 2026 Insider
Pieper Steven sold 5,000 shares
See Remarks @ $9.41 ($47.0K)
Sep 18, 2026 short_volume
Sep 9, 2026 SEC Short Volume: XERS — 63.2% short (0.5M / 0.8M)
Short: 524,024 | Exempt: 300 | TRF Vol: 829,370 | Short Ratio: 63.2% | Off-exchange volume (dark poo
Xeris Biopharma hosted a program overview webinar detailing its comprehensive development plan for XP-8121, an investiga
8-K — Impact 6/10
Three Xeris Biopharma insiders (McCulloch, Hecht, Pieper) sold a combined $311K in open-market shares on September 1, 20
CLUSTER — Impact 3/10
Xeris Biopharma reported Q2 2026 total revenue of $92.1M (+29% YoY) and net product revenue of $91.0M (+34% YoY), driven
8-K — Impact 7/10
Jun 30, 2026 Inst.
Nuveen, LLC — ADD
4,385,141 shares ($34.7M)
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
85% rate it Buy or better · 13 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 10, 2026 | Leerink Partners | MAINTAIN | Outperform | 49% |
| Aug 20, 2026 | Barclays | MAINTAIN | Overweight | 54% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 5 | 6 | 2 | 0 | 0 | 85% | |
| Aug 1, 2026 | 5 | 6 | 2 | 0 | 0 | 85% | |
| Jul 1, 2026 | 5 | 6 | 2 | 0 | 0 | 85% | |
| Jun 1, 2026 | 5 | 6 | 2 | 0 | 0 | 85% | |
| May 1, 2026 | 5 | 6 | 2 | 0 | 0 | 85% | |
| Apr 1, 2026 | 5 | 6 | 2 | 0 | 0 | 85% | |
| Mar 1, 2026 | 5 | 6 | 2 | 0 | 0 | 85% | |
| Feb 1, 2026 | 5 | 6 | 2 | 0 | 0 | 85% |
Price targets
Where 7 covering analysts think XERS trades over the next 12 months.
$12.29 +35.3% upside Strong Buy
Current$9.08 Low$8.00 Median$12.00 High$18.00 7 analysts
$8.00$18.00
Analyst rating None as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
14 SEC filing reports analyzed · 3 bullish, 1 bearish, 0 mixed, 10 neutral · avg impact 3.4/10.
BULLISH8-K6/10
Xeris Biopharma hosted a program overview webinar detailing its comprehensive development plan for X
Sep 9, 2026
NEUTRALCLUSTER3/10
Three Xeris Biopharma insiders (McCulloch, Hecht, Pieper) sold a combined $311K in open-market share
Sep 1, 2026
BULLISH8-K7/10
Xeris Biopharma reported Q2 2026 total revenue of $92.1M (+29% YoY) and net product revenue of $91.0
Aug 6, 2026
NEUTRALCLUSTER2/10
Two non-C-suite insiders at Xeris Biopharma sold a combined $254K in open-market transactions over a
Aug 5, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 18, 2026
short_volume
Short Volume: XERS — 63.2% short (0.5M / 0.8M)
Short: 524,024 | Exempt: 300 | TRF Vol: 829,370 | Short Ratio: 63.2% | Off-exchange volume (dark pool + OTC)
Aug 6, 2026
earnings_calendar
XERS Q2 2026 Earnings Scheduled — 2026-08-06
Aug 6, 2026
short_volume
Short Volume: XERS — 64.0% short (0.9M / 1.4M)
Short: 910,942 | Exempt: 126,356 | TRF Vol: 1,424,067 | Short Ratio: 64.0% | Off-exchange volume (dark pool + OTC)
Jul 15, 2026
short_volume
Short Volume: XERS — 59.1% short (0.3M / 0.5M)
Short: 315,457 | Exempt: 6,977 | TRF Vol: 533,444 | Short Ratio: 59.1% | Off-exchange volume (dark pool + OTC)
Jul 15, 2026
short_interest_report
Short Interest: XERS down 21% to 10.1M shares
Settlement 2026-07-15 | Days to cover: 4.38 | ≈5.84% of shares outstanding (est.)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.02 | $-0.15–$0.05 | 0.0% | +0.0% | 1↑ 1↓ | $0.1B | 3 |
| Next Q | $0.06 | $0.05–$0.06 | -8.3% | -67.6% | 1↑ 2↓ | $0.1B | 2 |
| Current FY | $-0.00 | $-0.06–$0.08 | 0.0% | +0.0% | 0↑ 3↓ | $0.4B | 3 |
| Next FY | $0.39 | $0.25–$0.63 | 11811.7% | +0.0% | 3↑ 0↓ | $0.5B | 3 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.020 | — |
| 7d ago | $-0.020 | — |
| 30d ago | $-0.020 | — |
| 60d ago | $0.040 | -0.060 |
| 90d ago | $0.043 | -0.063 |
Institutional ownership
Which big funds own XERS (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $667.7M total value (84,326,759 shares) as of 2026-Q2. Top holders: BlackRock,, D., VANGUARD. Net buying activity: 30 institutions added/increased vs 16 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 14,525,539 | $115.0M | 17.2% | — |
| D. E. Shaw & Co., Inc. | 7,804,758 | $61.8M | 9.3% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 7,340,229 | $58.1M | 8.7% | — |
| STATE STREET CORP | 4,821,566 | $38.2M | 5.7% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 4,718,183 | $37.4M | 5.6% | — |
| Nuveen, LLC | 4,385,141 | $34.7M | 5.2% | ADD +50.4% |
| Qube Research & Technologies Ltd | 2,893,749 | $22.9M | 3.4% | TRIM -29.7% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 2,626,208 | $20.8M | 3.1% | — |
| WELLINGTON MANAGEMENT GROUP LLP | 2,365,103 | $18.7M | 2.8% | — |
| MORGAN STANLEY | 2,337,096 | $18.5M | 2.8% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| Nuveen, LLC | ADD | 2,916,598 | 4,385,141 | +50.4% | $34.7M |
| Qube Research & Technologies Ltd | TRIM | 4,114,425 | 2,893,749 | -29.7% | $22.9M |
| FEDERATED HERMES, INC. | ADD | 856,813 | 1,434,433 | +67.4% | $11.4M |
| BANK OF AMERICA CORP /DE/ | ADD | 874,397 | 1,397,050 | +59.8% | $11.1M |
| JPMORGAN CHASE & CO | ADD | 612,479 | 1,058,067 | +72.8% | $8.2M |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | DOUBLED | 133,760 | 972,880 | +627.3% | $7.7M |
| FMR LLC | ADD | 513,076 | 644,057 | +25.5% | $5.1M |
| ROYCE & ASSOCIATES LP | ADD | 256,087 | 461,153 | +80.1% | $3.7M |
| Man Group plc | ADD | 276,422 | 455,380 | +64.7% | $3.6M |
| BNP PARIBAS FINANCIAL MARKETS | ADD | 262,787 | 430,488 | +63.8% | $3.4M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
12 insiders, 50 transactions. Net -$3.4M — $0.00 bought, $3.4M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Oct 1, 2026 | McCulloch Kevin | See Remarks | SELL | 15,000 | $9.41 | $141.1K |
| Oct 1, 2026 | Hecht Beth | See Remarks | SELL | 16,666 | $9.41 | $156.8K |
| Oct 1, 2026 | Pieper Steven | See Remarks | SELL | 5,000 | $9.41 | $47.0K |
| Sep 28, 2026 | McCulloch Kevin | See Remarks | SELL | 25,000 | $10.00 | $250.0K |
| Sep 1, 2026 | Pieper Steven | See Remarks | SELL | 5,000 | $8.50 | $42.5K |
| Sep 1, 2026 | Hecht Beth | See Remarks | SELL | 16,666 | $8.49 | $141.4K |
| Sep 1, 2026 | McCulloch Kevin | See Remarks | SELL | 15,000 | $8.49 | $127.3K |
| Aug 12, 2026 | Pieper Steven | See Remarks | SELL | 5,000 | $8.50 | $42.5K |
| Aug 3, 2026 | McCulloch Kevin | See Remarks | SELL | 15,000 | $8.02 | $120.2K |
| Aug 3, 2026 | Hecht Beth | See Remarks | SELL | 16,666 | $8.01 | $133.6K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for XERS.
Shares short
8,058,977
Settlement Sep 15, 2026
Change vs prior
+0.2%
Semi-monthly cycle
Days to cover
4.8
At avg daily volume
Of shares outstanding
≈4.4%
Estimate — not % of float
All XERS filing & press-release reports (14)
- 8-K reportSep 9, 2026
- CLUSTER reportSep 1, 2026
- 8-K reportAug 6, 2026
- CLUSTER reportAug 5, 2026
- CLUSTER reportJul 8, 2026
- 8-K reportJul 3, 2026
- CLUSTER reportJul 3, 2026
- 3 reportJul 2, 2026
- INST-CLUSTER reportJun 12, 2026
- CLUSTER reportJun 5, 2026
- CLUSTER reportJun 5, 2026
- 144 reportJun 5, 2026
- 144 reportJun 4, 2026
- 8-K reportFeb 27, 2026